Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
KHK-IN-1
Cat. No.:
OB0425LY-093
Appearance:
Solid
Purity:
≥95%
Identity:
Confirmed by NMR.
Size:
Add to basket
Product Overview
Description:
KHK-IN-1 is a small molecule compound that inhibits citrate kinase (KHK) and has important implications for metabolic diseases.
Synonyms:
1303469-70-6; 8-N-(Cyclopropylmethyl)-4-N-(2-methylsulfanylphenyl)-2-piperazin-1-ylpyrimido[5,4-d]pyrimidine-4,8-diamine; N8-(Cyclopropylmethyl)-N4-[2-(methylthio)phenyl]-2-(1-piperazinyl)-pyrimido[5,4-d]pyrimidine-4,8-diamine
CAS No.:
1303469-70-6
Compound CID:
53348216
Formula:
C21H26N8S
Formula Weight:
422.55
Specification
Target:
Ketohexokinase
Pathway:
Metabolic enzyme/Protease
Storage:
Storage at -20°C.
Applications:
KHK-IN-1 can be used to study drug development for metabolic syndrome, diabetes-related diseases and obesity-related conditions.
